Methods and compositions for treating cystic fibrosis

Details Methods and compositions for treating cystic fibrosis Methods and compositions for treating cystic fibrosis

1997-02-27

1998-11-10

Tsang, Cecilia J.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

514540, 514588, 514619, 560 33, 564 59, 564160, 564161, 564192, A01N 3718, A61K 3800

Patent

active

058344217

ABSTRACT:
Methods and compositions for treating CF by mobilizing mutant forms of CFTR, which retain at least some functional activity, to the plasma membrane where they can mediate chloride ion transport are disclosed.

REFERENCES:
patent: 5637613 (1997-06-01), Renault et al.
patent: 5674898 (1997-10-01), Cheng et al.
Cheng, S.H. et al. Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis. Cell 63:827-834 (1990).
Jensen, T.J., Loo, M.A., Pind, S., Williams, D.B., Goldberg, A.L., and Riordan, J.R. Multiple proteolytic systems including proteasome, contribute to CFTR processing. Cell 83:129-135 (1995).
Ward, C.L., Omura, S., & Kopito, R.R. Degradation of CFTR by the uniquitin-proteasome pathway. Cell 83:121-127 (1995).
Denning, G.M., Anderson, M.P., Amara, J.F., Marshall, J., Smith, A.E., and Welsh, M.J. Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive. Nature 358:761-764 (1992).
Brown, C.R., Hong-Brown, L.Q., Biwersi, J., Verkman, A.S., and Welch, W.J. Chemical chaperones correct the mutant phenotype of the .increment.F508 cystic fibrosis transmembrane conductance regulator protein. Cell Stress & Chaperones 1:117-125 (1996).
Sato, S., Ward, C.L., Krouse, M.E., Wine, J.J., & Kopito, R.R. Glycerol reverses the misfolding phenotype of the most common cystic fibrosis mutation. J. Biol. Chem. 271:635-638 (1996).
Cheng, S.H. et al. Functional activation of the cystic fibrosis trafficking mutant .kappa.-CFTR by overexpression. Am. J. Physiol. 268:L615-L624 (1995).
Hartl, F.U. Molecular chaperones in cellular protein folding. Nature 381:571-580 (1996).
Yang, Y., Janich, S., Cohn, J.A., and Wilson, J.M. The common variant of cystic fibrosis transmembrane conductance regulator is recognized by hsp70 and degraded in a pre-Golgi nonlysosomal compartment. Proc. Natl. Acad. Sci. USA 90:9480-9484 (1993).
Pind, S., Riordan, J.R., and Williams, D.B. Participation of the endoplasmic reticulum chaperone calnexin (p88, IP90) in the biogenesis of the cystic fibrosis transmembrane conductance regulator. J. Biol. Chem. 269:12784-12788 (1994).
Umezawa, H. et al. Structure of antitumor antibiotic, spergualin. J. Antibiotics 34:1622-1624 (1981).
Nadler, S.G., Tepper, M.A., Schacter, B., and Mazzucco. Interaction of the immunosuppressant deoxyspergualin with a member of the Hsp70 family of heat shock proteins. Science 258:484-486 (1992).
Nadeau, K., Nadler, S.G., Saulnier, M., Tepper, M.A., and Walsh, C.T. Quanitation of the interaction of the immunosuppressant deoxyspergualin and analogs Hsc70 and Hsp90. Biochemistry 33:2561-2567.
Marshall, J. et al. Stoichiometry of recombinant cystic fibrosis transmembrane conductance regulator in epithelial cells and its functional reconstitution into cells in vitro. J. Biol. Chem. 269:2987-2995 (1994).
Jefferson, D.M. et al. Expression of normal and cystic fibrosis phenotype by continuous airway epithelial cell lines. Am. J. Physiol. 259:L496-L505 (1990).
Tepper, M.A., Nadler S.G., Esselstyn, J.M., and Sterbenz, K.G. Deoxyspergualin inhibits .kappa. light chain expression in 70Z/3 pre-B cells by blocking lipoplysaccharide-induced NF-.kappa.B activation. J. Immunol. 155:2427-2436 (1995).
Yankaskas, J.R. et al. Papilloma virus immortalized tracheal epithelial cells retain a well-differentiated phenotype. Am. J. Physiol. 264:C1219-C1230 (1993).
Grubman, S.A. et al. Correction of the cystic fibrosis defect by gene complementation in human intrahepatic biliary epithelial cell lines. Gastroenterology 108:584-592 (1995).
Dalemans, W. et al. Altered chloride ion channel kinetics associated with .increment.F508 cystic fibrosis mutation. Nature 354:526-528 (1991).
Howard, M., Frizzell, R.A., and Bedwell, D.M. Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations. Nature Genetics 2:467-469 (1996).
Rubenstein, R.C., Brusilow, S.W., Hamosh, A., and Zeitlin, P.L. Clinical trials of 4-phenylbutyrate for correction of sweat duct abnormalities in .increment.F508 homozygous cystic fibrosis patients. Pediat. Pulmonology 13:259 (1996).
NoBner, E., Goldberg, J.E., Naftzger, C., Lyu, S.C., Clayberger, C., and Krensky, A.M. HLA-derived peptides which inhibit T cell function bind to members of the heat-shock protein 70 family. J. Exp. Med. 183:339-348 (1996).
Yang, I.C.H., Cheng, T.H., Wang, F., Price, E.M., and Hwang, T.C. Modulation of CFTR chloride channels by calyculin A and genistein. Am. J. Physiol. 272:C142-C155 (1997).
Hamill, O.P., Marty, A., Neher, E., Sakmann, B., and Sigworth, F.J. Improved patch clamp techniques for high resolution current recordings from cells and cell-free membrane patches. Pfluger Archiv. 391:85-100 (1981).
Egan, M.E., et al. Defection regulation of outwardly rectifying chloride channels by protein kinase A corrected by insertion of CFTR. Nature 358:581-584 (1992).
Anderson, M.P. et al. Demonstration that CFTR is a chloride channel by alteration of its anion selectivity. Science 253:202-205 (1991).
Nadler, S.G. et al. Elucidating the Mechanism of Action of the Immunosuppressant 15-Deoxyspergualin. Therapeutic Drug Monitoring 17:700-703 (1995).
Halloran, P.F. Molecular mechanisms of new immunosuppressants. Clinical Transplantation 10:118-123 (1996).
Edgington, S.M. Therapeutic Applications of Heat Shock Proteins. Bio/Technology 13:1442-1444 (1995); and.
Sheppard D.N. and Ostedgaar, L.S. Understanding how cystic fibrosis mutations cause a loss of CI-channel function. Mol. Med. Today 2(7):290-297 (1996).
Medline AN 97365770, Brown et al., Cell Stress Chaperones (1996 Jun.) 1(2) 117-25.
Yang et al., PNAS USA vol. 90 pp. 9480-9484 Oct. 1993.

Affiliated with

Also associated with

Rating

Methods and compositions for treating cystic fibrosis does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods and compositions for treating cystic fibrosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for treating cystic fibrosis will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1516710